The Women’s Cancer Care and Research Program (WeCARE) is committed to community-informed science that will foster dialogue and promote health equity and diversity. The goal is to fuel clinical research and trial development to benefit people with breast and gynecologic cancers (ovarian, cervical, uterine, vaginal, and vulvar).
“We want to enhance our portfolio of team-based, community-engaged, and multidisciplinary research in breast and gynecologic cancers at UC Davis,” said Laura Fejerman, one of the directors of WeCARE and associate director of the cancer center’s Office of Community Outreach and Engagement.
Two clinical scientists, Alexander Borowsky, Department of Pathology and Laboratory Medicine professor and director of molecular diagnostics, and Gary Leiserowitz, chair of the UC Davis Department of Obstetrics and Gynecology, serve as WeCARE co-directors.
WeCARE program priorities:
- Prevention and early detection
- Care innovation
WeCARE will facilitate and support the development of prevention and early detection programs, care innovation, and research for breast and gynecologic cancers. The program will leverage innovative and multidisciplinary approaches to reduce the cancer burden and achieve health equity.
“We appreciate the backing of the cancer center to provide $50,000 in seed funding that will grow innovative multidisciplinary science to advance breast and gynecologic cancer equity,” Fejerman said.